Subscribe
shutterstock_1139644889_martyn_jandula
Martyn Jandula / Shutterstock.com
30 April 2020Big PharmaSarah Morgan

CJEU hands down SPC guidance in Royalty Pharma

The Court of Justice of the European Union (CJEU) has handed down its  decision in Royalty Pharma, providing highly-anticipated guidance on supplementary protection certificates (SPCs).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
SPCs: a deep dive into CJEU case law
23 June 2020   The CJEU’s many attempts to clarify the law around SPCs has created more questions than answers, as Katie Cambrook and Ben Millson of Bristows explain.
Big Pharma
Royalty Pharma: welcome clarity mixed with unwelcome ambiguity
15 May 2020   The CJEU’s decision in Royalty Pharma has provided much-anticipated guidance on supplementary protection certificates but has left a lot of uncertainty. Was this the best the CJEU could come up with? Beatriz San Martin of Arnold & Porter reports.
Big Pharma
CJEU puts further brakes on SPCs
22 March 2019   The Court of Justice of the European Union yesterday, March 21, handed down a supplementary protection certificate decision referred to it by the English High Court.


Editor's picks

Life sciences leaders recognised at LSPN Awards USA 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

Editor's picks

Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025
Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025

More on this story

Big Pharma
SPCs: a deep dive into CJEU case law
23 June 2020   The CJEU’s many attempts to clarify the law around SPCs has created more questions than answers, as Katie Cambrook and Ben Millson of Bristows explain.
Big Pharma
Royalty Pharma: welcome clarity mixed with unwelcome ambiguity
15 May 2020   The CJEU’s decision in Royalty Pharma has provided much-anticipated guidance on supplementary protection certificates but has left a lot of uncertainty. Was this the best the CJEU could come up with? Beatriz San Martin of Arnold & Porter reports.
Big Pharma
CJEU puts further brakes on SPCs
22 March 2019   The Court of Justice of the European Union yesterday, March 21, handed down a supplementary protection certificate decision referred to it by the English High Court.

More on this story

Big Pharma
SPCs: a deep dive into CJEU case law
23 June 2020   The CJEU’s many attempts to clarify the law around SPCs has created more questions than answers, as Katie Cambrook and Ben Millson of Bristows explain.
Big Pharma
Royalty Pharma: welcome clarity mixed with unwelcome ambiguity
15 May 2020   The CJEU’s decision in Royalty Pharma has provided much-anticipated guidance on supplementary protection certificates but has left a lot of uncertainty. Was this the best the CJEU could come up with? Beatriz San Martin of Arnold & Porter reports.
Big Pharma
CJEU puts further brakes on SPCs
22 March 2019   The Court of Justice of the European Union yesterday, March 21, handed down a supplementary protection certificate decision referred to it by the English High Court.

More features

Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
LSPN: Counsel grapple with AI’s impact on training and critical thinking
'Nothing can stand in the way of our work': Ukraine resumes IP system
LSPN: Trump's policy storm causing chaos and confusion
Taylor Wessing expands in Europe with Paris team
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
ResMed voids sleep apnoea tech patent at PTAB